secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001628280-26-020517
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics releases updated corporate presentation focused on T cell engagers for solid tumors
--------------------------------------------------------------------------------

- Presentation updated March 23, 2026 for investor and analyst meetings.
- Slides emphasize advancing T cell engager platform for solid tumors; no financial or clinical data disclosed.
- Slides 15 and 32 incorporated into Item 8.01, but specific content not detailed in filing.
- Previous presentation replaced; no new pipeline milestones, partnerships, or financing announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026020517/0001628280-26-020517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026020517/cntx-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-020517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer